LSD1-IN-13 hydrochloride 

LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines^[1].

IC₅₀: 24.43 ± 1.08 nM (LSD1), 5.00 ± 0.28 μM (LSD2), >100 μM (MAO-A), >100 μM (MAO-B)^[1]

LSD1-IN-13 hydrochloride (compound 7e) shows good selectivity over LSD2 (205-fold) and MAOs (>4000-fold)^[1].
LSD1-IN-13 hydrochloride shows potent and selective antiproliferative activity in MV-4-11, with an IC₅₀ of 1.36 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LSD1-IN-13 hydrochloride (compound 7e) (MV-4-11 xenograft mice, 0-20 mg/kg, Orally, daily for 15 days) suppresses tumor growth significantly in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

448.02

C₂₃H₃₀ClN₃O₂S

2170347-90-5

O=S(N1CCC2=C1C=CC([C@H]3[C@H](NCC4CCNCC4)C3)=C2)(C5=CC=CC=C5)=O.[H]Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li C, et al. Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors. J Med Chem. 2022 Mar 10;65(5):4335-4349.  [Content Brief]